


CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*






Disclosures

Received compensation from Novartis
for attending an Advisory Board,
March 2022

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*



Tyrosine kinase inhibitors

Imatinib 400 mg qd
Dasatinib 100 mg
Nilotinib 300 mg bid
Bosutinib 400 mg qd

Front line therapy

Which TKI to choose?

Consider disease status; low, intermediate or high

Comorbidities

Treatment related side effects/risk factors

Monitoring specific to medication

Drug/drug interactions

Patient adherence


Tyrosine kinase inhibitors

Imatinib 400 mg qd
Dasatinib 100 mg
Nilotinib 300 mg bid
Bosutinib 400 mg qd

Front line therapy

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*



Tyrosine kinase inhibitors

Imatinib 400-600 mg qd
Dasatinib 100 mg
Nilotinib 400 mg bid
Bosutinib 500 mg qd

*Second line/
subsequent therapy*

Resistance/intolerance >2 TKIs or *T315i mutation

Ponatinib 15 mg qd, *30-45 mg qd

Asciminib 40 mg bid or 80 mg qd, * 200 mg bid


Tyrosine kinase inhibitors

Imatinib 400-600 mg qd
Dasatinib 100 mg
Nilotinib 400 mg bid
Bosutinib 500 mg qd

***Second line/
subsequent therapy***

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*



Monitoring PCRs for Bcr/Abl

>10 @ 3 mos [yellow], 6-12 mos [red]

>1-10 @ 3-6 mos [dark green], 12 mos [yellow]

>0.1-1 @ 3-6 mos [dark green], 12 mos [light green]

<0.1 @ 3-12 mos [dark green]

***Treatment
milestones***

Considerations for suboptimal response

- Medication adherence
- Drug/drug interactions
- Intolerance/Adverse events
- Abl sequencing for mutational analysis
- Dose increase
- Switch to another TKI
- Clinical trial and/or HSCT

Monitoring PCRs for Bcr/Abl

>10 @ 3 mos [yellow], 6-12 mos [red]

>1-10 @ 3-6 mos [dark green], 12 mos [yellow]


>0.1-1 @ 3-6 mos [dark green], 12 mos [light green]

<0.1 @ 3-12 mos [dark green]

***Treatment
milestones***

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*





Major Molecular Response

Goals of treatment:

- Long term survival
- Maximize treatment response, minimize treatment related side effects
- Treatment free remission [TFR]

Optimal response

Treatment free remission

- TKI for at least 3 years, > 2 years of MR4.5 (<0.0032)
- PCRs q 4-6 weeks from month 1-6, then q 6-8 weeks from month 7-12, then q 3 months thereafter
- Monitoring, indefinitely



Major Molecular Response


Goals of treatment:

- Long term survival
- Maximize treatment response, minimize treatment related side effects
- Treatment free remission [TFR]

Optimal response

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*



Dose reduction

Imatinib* 400 mg qd; 300-200 mg qd
Dasatinib 100 mg; 80-20 mg qd
Nilotinib 300 mg bid; 400 mg-300 mg qd
Bosutinib 400 mg qd; 300-200 mg qd

***Optimal
response***

Disease status & treatment response

- PCRs monitoring q 3 months
- Dose adjustments
- Management of treatment related side effects

Questions?

Diana Brewer, PA-C
Assistant Professor

Center for Hematologic Malignancies
OHSU Knight Cancer Institute
brewerd@ohsu.edu

Dose reduction

Imatinib* 400 mg qd; 300-200 mg qd
Dasatinib 100 mg; 80-20 mg qd
Nilotinib 300 mg bid; 400 mg-300 mg qd
Bosutinib 400 mg qd; 300-200 mg qd

***Optimal
response***

CP-CML

*Annual Hematology
and Breast Cancer
Update 2022*

